tradingkey.logo

Kenvue slumps ahead of Trump's 'important' announcement on autism findings

ReutersSep 22, 2025 2:57 PM

** Shares of Tylenol maker Kenvue KVUE.N fall 7.1% to a record low of $17.03

** U.S. President Donald Trump said on Saturday his administration would make announcement about its autism findings on Monday, but declined to offer specifics

** The Wall Street Journal reported earlier this month that Health Secretary Robert F. Kennedy Jr. plans to announce that use of KVUE's popular over-the-counter pain medication, Tylenol, by pregnant women is potentially linked to autism, contrary to medical guidelines that say it is safe to use

** "We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with any suggestion otherwise and are deeply concerned with the health risk this poses for expecting mothers," Kenvue says in a statement on Monday

** Acetaminophen is the active ingredient in Tylenol

** Including session moves, shares down 19.6% YTD

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI